An observational study in Glaucoma, Open-Angle, sponsored by Glaukos Corporation. Status unknown at 24 sites in United States. Per ClinicalTrials.gov, last updated 2021-10-20.
Sponsored by Glaukos Corporation · Observational
Long term follow up of subjects in the IDE study for iStent Inject to monitor safety
To evaluate the long -term rate of clinically relevant complications associated with iStent inject® placement and stability in subjects who have completed participation of the IDE clinical trial (GC-008).
929 studies on the registry are indexed under Glaucoma, Open-Angle; 122 are open to participants now.
This study's planned enrollment of 475 is above the median of 101 across 182 observational studies indexed under Glaucoma, Open-Angle.
Browse Glaucoma, Open-Angle studies →Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
Counted across the registry records on this site, refreshed daily.
Up to 475 eyes of 475 subjects. This is based on the number of randomized subjects in the GC-008 study followed for 24 months.
Exclusion Criteria:
iStent inject Placement and Stability
Rate of clinically relevant complications associated with iStent inject placement and stability.
Time frame: 60 Months
Sight-Threatening Adverse Events
Rate of occurrence of sight-threatening adverse events
Time frame: 60 Months
Secondary Surgical Interventions
Rate of Secondary Surgical Interventions
Time frame: 60 Months
Adverse Events
Rate of other adverse Events
Time frame: 60 Months
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Glaukos Corporation